Impact of preoperative statin medication on long-term outcomes after pancreatoduodenectomy for ductal adenocarcinoma: an international multicentric cross-sectional study

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, one of the most lethal cancers with a 5-year survival rate of less than 10% (Fristrup et al. 2016). Radical surgical resection represents the backbone of any curative approach. However, surgical interventions, such as pancreatoduodenectomy (PD) are complex and its associated postoperative morbidity is still high. Despite recent advances in surgical techniques and perioperative care, the long-term outcomes for patients with pancreatic cancer remain dismal (Conroy et al. 2018). There is a need to find novel approaches that could improve survival rates by reducing early cancer recurrence.

Statins are nowadays widely used drugs to lower serum cholesterol levels and to reduce the risk of cardiovascular disease by a direct inhibition of the enzyme HMG (hydroxymethylglutaryl)-CoA-reductase. Recently, there has been growing interest in the potential anti-tumor effects of statins (Yuan et al. 2022). Several preclinical and clinical studies have suggested that statins may inhibit the growth and dissemination of pancreatic cancer cells (Tamburrino et al. 2020). However, the impact of statin use on long-term outcomes in patients undergoing PD for pancreatic cancer is not well established.

The aim of this cross-sectional study was to evaluate whether preoperative statin use is associated with improved long-term survival and reduced cancer recurrence in patients undergoing upfront PD for ductal adenocarcinoma of the pancreatic head.

The present study assessing the impact of perioperative statin treatment on the long-term outcomes after surgery for PDAC did not find a difference in OS and DFS in this cohort. Independent predictors of OS were lymph node involvement, tumor differentiation, and adjuvant chemotherapy.

It has been hypothesized that statin had anti-cancer properties. Via the inhibition of HMG-CoA-reductase, statins block the transformation of HMG-CoA to geranyl-pyrophosphate and farnesyl-pyrophosphate (Di Bello et al. 2020). This blockage has an effect on decreasing not only cholesterol, but also inflammation, tissue remodeling, angiogenesis, and cell proliferation, as well as inducing apoptosis (Di Bello et al. 2020). The latter effects explain the potential anti-cancer properties of statins. Some studies have shown that patients with statin treatment had better survival in several types of solid cancers. Meta-analyses confirmed these findings for example in gastric and colorectal cancers (Cai et al. 2015; Yuan et al. 2022). In pancreas cancer, a 2019 systematic review and meta-analysis of 27 studies showed that statin users had a reduced risk of developing PDAC compared to patients without statin treatment (OR 0.70, 95% CI 0.60–0.82, p < 0.0001)(Archibugi et al. 2019). Moreover, a recent Norwegian study based on a nationwide registry found that patients under statin medication (n = 621) had better OS than non-statin users (n = 1993, HR: 0.87, 95% CI 76–97) (Støer et al. 2021). A 2018 meta-analysis found similar results with an improved survival in pancreatic cancer patients under statin treatment (HR: 0.75, 95% CI 0.59–0.90) (Jian-Yu et al. 2018). Significant heterogeneity between included studies was noticed. A 2020 meta-analysis even found that the positive effect on survival was more important among surgically resected pancreatic cancer patients (HR 0.5, 95% CI 0.32–0.76) (Tamburrino et al. 2020). It is important to bear in mind that observational studies might have selection and immortal-time biases, so the preceding findings need to be interpreted cautiously. A large study using the SEER-Medicare database (n = 17,372) and the inverse-probability weighting method to eliminate immortal-time bias showed that statin treatment initiated within 6 months after cancer diagnosis did not improve 3-year OS (Emilsson et al. 2018).

The present study assessed survival in patients who have been operated on, which is different from most of the observational studies on statins in cancer, where only non-operated patients are included, or a heterogeneous cohort of operated and non-operated patients is evaluated. In the studied specific cohort of PDAC patients operated upfront, it is interesting to hypothesize why no survival difference was found. First, it corroborates other studies on operated and non operated PDAC patients suggesting that statin treatment has no effect on long-term survival. For instance, a similar cross-sectional study by Tamburrino et al. including 430 patients who underwent pancreatic resection showed that DFS and disease-specific survival (DSS) were not influenced by a statin treatment (median DSS: statin, 37 vs. no statin, 34 months, p = 0.878)(Tamburrino et al. 2021). Of note, in the previously cited study, not all patients underwent pancreatoduodenectomy (69%) and 39% of the patients had neoadjuvant chemotherapy, which is different from the present study. The high rate of adjuvant chemotherapy after PDAC resection in this cohort (77%) might be another explanation, as adjuvant chemotherapy has been shown to improve OS of pancreatic cancer patients, such as in the present cohort. Other potential hypotheses are that the treatment duration and the therapeutic adherence to the statin treatment are important determinants. Unfortunately, these details were not available in this cohort. A final hypothesis pertains to the type of statin treatment. A meta-analysis by Tamburrino et al. found that rosuvastatin was associated with better outcomes in pancreas cancer patients, on the contrary of other statin types (Tamburrino et al. 2020). The present study included different statin subtypes without restriction.

In the present cohort, only patients who were operated upfront were included. The reason for not including patients who underwent neoadjuvant chemotherapy and for including only patients with PDAC of the pancreatic head was to have a cohort as homogeneous as possible. If such patients were included, it would have been necessary to take into account this supplementary element in the multivariable analysis or perform a subgroup analysis. Moreover, as neoadjuvant treatment was only recently implemented in the centers included in this study and various chemotherapy regimens were used, the number of patients with neoadjuvant would have been relatively small compared to the rest of the cohort and the heterogeneity more important.

Some limitations of this study should be mentioned. Data on the subtype of statin treatment (e.g., atorvastatine, simvastatine, others) were not available. Furthermore, the duration of the statin treatment was not known at time of data analysis. It was only known if patients had the statin treatment for more than a month prior to surgery. Another potential important information is the compliance to the statin treatment that was not available in the chart review. The retrospective design of the study has inherent limitations, such as errors during collection data or missing data.

This exploratory study suggests that using statin as an anti-cancer treatment for PDAC patients might not be useful in patients who undergo upfront surgery. Results might be different in a population of PDAC patients who benefit from neoadjuvant chemotherapy or in a patient cohort of borderline or locally advanced PDAC. This would be interesting to evaluate in future cohort or cross-sectional studies if statins impact survival in these subtypes of pancreatic cancer patients. Moreover, results of this study cannot be generalized to overall cancer patients, in particular patients who did not have surgery as upfront oncological treatment.

In summary, this international multicentric cross-sectional study did not identify preoperative statin treatment as a prognostic factor of survival in patients who underwent upfront surgery for PDAC. Factors predictive of OS were related to the biology of the tumor and adjuvant chemotherapy.